NAVB stock: buy or sell?
May 22nd, 2020
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics.
Should I buy NAVB stock?Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best time to buy them. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
None of our preferred buy setups matches with Navidea Bio stock situation right now, therefore this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Navidea Biopharmaceuticals stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.Unfortunately, we couldn't find any rating for NAVB stock for the last 30 days.
NAVB stock analysis
Navidea Biopharmaceuticals boosted a super good 91.34% and closed at $2.43.
Navidea Biopharmaceuticals boosted a super good 91.34% and closed at $2.43. On May/4 NAVB price bounced up over the SMA of 200 days demonstrating to be a significant support for this stock. Since February when SMA100d and SMA200d crossed up, NAVB price gained $1.38 per share (131.43%). From a daily perspective, NAVB is in a short term uptrend after plotting its last bottom ($0.81, on April/29) higher than the previous bottom, and its last top ($1.52, on Wednesday) also over the previous top. Now trading in between its last bottom and last top NAVB might consolidate in a plain range, waiting to break out over $1.52 or down under $0.81.
Navidea Bio shares boosted 120.91% last week, ending at $2.43. Counting this, it's been 4 green weeks in a row, gaining $1.73 or 233.78%. Late April NAVB plunged a chilling -5.71% in just one week.
Since early May when NAVB stock price broke up the SMA40w line, it gained $1.58 (185.88%). Late January, SMA20w and SMA40w crossed up triggering a rise of 76.09%.
NAVB stock price history
NAVB stock went public on November 10th, 1992 with a price of $130.001. Since then, NAVB stock lost a -98.10%, with a yearly average of -3.60%.
1: Adjusted price after possible price splits or reverse-splits.
NAVB stock historical price chart
NAVB stock reached 52-week highs on Friday at $3.50, and all-time highs 1996-03-25 with a price of 465.
NAVB stock price targetHow much a stock will be priced tomorrow or next week is quite unpredictable However, many stock price predictions are published every day by banks, financial institutions and independent analysts. You should not follow the analysts' NAVB stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we have not detected any price target for Navidea Bio stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per Share, when Navidea Biopharmaceuticals presented its last earnings report, it . Unfortunately, reported EPS is not yet available in our database.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual revenues report draw a hair-raising slide of -35.41% to $1.17 M dollars. In the same way, its profit margin (compared to revenues) collapsed to -1,378.02%, that is $-16.11 million.
|2013||$1.13 M||-||$-42.70 M-3778.8%||-|
|2014||$6.27 M||455.30%||$-35.73 M-569.4%||-16.33%|
|2015||$13 M||111.15%||$-27.56 M-208.0%||-22.85%|
|2016||$22 M||65.82%||$-14.31 M-65.1%||-48.09%|
|2017||$1.81 M||-91.76%||$75 M4139.7%||-623.79%|
|2018||$1.17 M||-35.41%||$-16.11 M-1378.0%||-121.50%|
Quarterly financial resultsNavidea Biopharmaceuticals posted $0.12 M in sales for 2018-Q4, a -48.45% decline compared to previous quarter. Reported quarter income marked $-3.16 M with a profit margin of -2,648.60%. Profit margin plummed a -997.50% compared to previous quarter when profit margin was -1,651.10%. When comparing turnover to same quarter last year, Navidea Bio sales marked a spooky correction and plunged a -69.80%. Looking back to recent quarterly results, Navidea Bio posted 2 negative quarters in a row.
|2017-Q1||$0.58 M||-||$-2.86 M-493.1%||-|
|2017-Q2||$0.61 M||5.44%||$-3.15 M-515.0%||10.14%|
|2017-Q3||$0.22 M||-63.43%||$-1.39 M-621.2%||-55.89%|
|2017-Q4||$0.40 M||76.66%||$-4.06 M-1027.0%||192.07%|
|2018-Q1||$0.28 M||-30.04%||$-6.74 M-2437.4%||66.04%|
|2018-Q2||$0.54 M||96.11%||$-2.39 M-441.6%||-64.47%|
|2018-Q3||$0.23 M||-57.31%||$-3.82 M-1651.1%||59.63%|
|2018-Q4||$0.12 M||-48.45%||$-3.16 M-2648.6%||-17.30%|
Navidea Bio ownershipHaving a look at Navidea Bio ownership structure gives valuable information about the company and its governance (insider ownership) or the amount of investors that are on the short side.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Navidea Bio, 49.21% of all outstanding shares are owned by its staff.
In case of Navidea Biopharmaceuticals stock, 3.57% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for NAVB stock account 0.00%, no big difference from last month.
For a better context understanding, the next table shows ownership data compared to other related companies:
|Market cap||$54.9 M|
|Total shares||22.6 M|
|Float shares||12.3 M|
|- Institutional holdings (%)||3.6%|
|- Insider holdings (%)||49.2%|
|Shares in short selling||0.0%|
|Friday, May 22nd, 2020|
|Day range||$2.26 - $3.50|
|Average true range||$0.28|
|50d mov avg||$0.88|
|100d mov avg||$1.04|
|200d mov avg||$0.90|
Navidea Bio performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We selected as the bechmarking frame for Navidea Bio stock.